Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 664 Thousand USD | -35.03% |
| 2021 | 1.02 Million USD | 99.61% |
| 2020 | 512 Thousand USD | -15.93% |
| 2019 | 609 Thousand USD | -15.88% |
| 2018 | 724 Thousand USD | -78.45% |
| 2017 | 3.36 Million USD | 5.33% |
| 2016 | 3.19 Million USD | -47.42% |
| 2015 | 6.06 Million USD | -13.3% |
| 2014 | 6.99 Million USD | 9.43% |
| 2013 | 6.39 Million USD | -6.98% |
| 2012 | 6.87 Million USD | 8.78% |
| 2011 | 6.32 Million USD | 51.46% |
| 2010 | 4.17 Million USD | 18.81% |
| 2009 | 3.51 Million USD | 6.84% |
| 2008 | 3.28 Million USD | 380.43% |
| 2007 | 684.23 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 134 Thousand USD | 28.85% |
| 2023 Q2 | 109 Thousand USD | -18.66% |
| 2022 FY | 664 Thousand USD | -35.03% |
| 2022 Q1 | 150 Thousand USD | -67.46% |
| 2022 Q3 | 126 Thousand USD | -55.63% |
| 2022 Q2 | 284 Thousand USD | 89.33% |
| 2022 Q4 | 104 Thousand USD | -17.46% |
| 2021 Q1 | 190 Thousand USD | 40.74% |
| 2021 Q2 | 156 Thousand USD | -17.89% |
| 2021 Q3 | 215 Thousand USD | 37.82% |
| 2021 Q4 | 461 Thousand USD | 114.42% |
| 2021 FY | 1.02 Million USD | 99.61% |
| 2020 Q3 | 137 Thousand USD | 19.13% |
| 2020 Q4 | 135 Thousand USD | -1.46% |
| 2020 FY | 512 Thousand USD | -15.93% |
| 2020 Q1 | 125 Thousand USD | 13.64% |
| 2020 Q2 | 115 Thousand USD | -8.0% |
| 2019 Q1 | 212 Thousand USD | 8.16% |
| 2019 Q4 | 110 Thousand USD | -19.71% |
| 2019 Q2 | 150 Thousand USD | -29.25% |
| 2019 Q3 | 137 Thousand USD | -8.67% |
| 2019 FY | 609 Thousand USD | -15.88% |
| 2018 Q1 | 358 Thousand USD | -52.65% |
| 2018 FY | 724 Thousand USD | -78.45% |
| 2018 Q4 | 196 Thousand USD | 86.67% |
| 2018 Q3 | 105 Thousand USD | 61.54% |
| 2018 Q2 | 65 Thousand USD | -81.84% |
| 2017 FY | 3.36 Million USD | 5.33% |
| 2017 Q4 | 756 Thousand USD | -11.89% |
| 2017 Q3 | 858 Thousand USD | 4.51% |
| 2017 Q2 | 821 Thousand USD | -11.24% |
| 2017 Q1 | 925 Thousand USD | 63.72% |
| 2016 Q2 | 707 Thousand USD | -31.36% |
| 2016 Q1 | 1.03 Million USD | -21.85% |
| 2016 FY | 3.19 Million USD | -47.42% |
| 2016 Q3 | 888 Thousand USD | 25.6% |
| 2016 Q4 | 565 Thousand USD | -36.37% |
| 2015 Q2 | 1.53 Million USD | -16.93% |
| 2015 FY | 6.06 Million USD | -13.3% |
| 2015 Q4 | 1.31 Million USD | -4.08% |
| 2015 Q3 | 1.37 Million USD | -10.25% |
| 2015 Q1 | 1.84 Million USD | 11.23% |
| 2014 Q2 | 1.6 Million USD | -17.22% |
| 2014 FY | 6.99 Million USD | 9.43% |
| 2014 Q3 | 1.79 Million USD | 11.77% |
| 2014 Q4 | 1.65 Million USD | -7.69% |
| 2014 Q1 | 1.94 Million USD | -5.6% |
| 2013 Q1 | 1.53 Million USD | -32.71% |
| 2013 FY | 6.39 Million USD | -6.98% |
| 2013 Q4 | 2.05 Million USD | 53.93% |
| 2013 Q3 | 1.33 Million USD | -9.43% |
| 2013 Q2 | 1.47 Million USD | -3.72% |
| 2012 FY | 6.87 Million USD | 8.78% |
| 2012 Q3 | 1.49 Million USD | -12.19% |
| 2012 Q4 | 2.27 Million USD | 52.31% |
| 2012 Q2 | 1.7 Million USD | 21.12% |
| 2012 Q1 | 1.4 Million USD | -28.26% |
| 2011 Q1 | 808.68 Thousand USD | -39.13% |
| 2011 Q2 | 1.69 Million USD | 109.61% |
| 2011 Q4 | 1.95 Million USD | 5.35% |
| 2011 FY | 6.32 Million USD | 51.46% |
| 2011 Q3 | 1.85 Million USD | 9.63% |
| 2010 Q3 | 579.2 Thousand USD | -61.76% |
| 2010 Q2 | 1.51 Million USD | 101.99% |
| 2010 Q4 | 1.32 Million USD | 129.39% |
| 2010 FY | 4.17 Million USD | 18.81% |
| 2010 Q1 | 749.94 Thousand USD | 23.26% |
| 2009 Q4 | 608.44 Thousand USD | -60.44% |
| 2009 Q2 | 856.24 Thousand USD | 68.15% |
| 2009 FY | 3.51 Million USD | 6.84% |
| 2009 Q1 | 509.21 Thousand USD | -61.86% |
| 2009 Q3 | 1.53 Million USD | 79.63% |
| 2008 Q2 | 506.93 Thousand USD | -3.55% |
| 2008 Q4 | 1.33 Million USD | 45.16% |
| 2008 Q3 | 919.71 Thousand USD | 81.42% |
| 2008 FY | 3.28 Million USD | 380.43% |
| 2008 Q1 | 525.59 Thousand USD | 0.0% |
| 2007 FY | 684.23 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 50.278% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 86.831% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 97.753% |
| Nascent Biotech, Inc. | 2.22 Million USD | 70.223% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.218% |
| Qrons Inc. | 643.67 Thousand USD | -3.157% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -70.446% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.844% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -59.816% |
| Skye Bioscience, Inc. | 13.54 Million USD | 95.099% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.235% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 86.498% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -153.7% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.224% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 77.231% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 55.789% |
| Mesoblast Limited | 5.9 Million USD | 88.75% |
| Marizyme, Inc. | 19.23 Million USD | 96.549% |
| Genus plc | 147.7 Million USD | 99.55% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 92.437% |
| Pharming Group N.V. | 225.49 Million USD | 99.706% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 67.589% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 50.505% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 92.037% |
| ContraFect Corporation | 56.88 Million USD | 98.833% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 84.939% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 55.097% |
| IMV Inc. | 37.7 Million USD | 98.239% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 76.204% |
| MultiCell Technologies, Inc. | 567.42 USD | -116920.902% |
| ONE Bio Corp. | 6.44 Million USD | 89.696% |
| Accustem Sciences Inc. | 3.74 Million USD | 82.276% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.227% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -24.821% |
| Q BioMed Inc. | 3.43 Million USD | 80.679% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 97.313% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 74.729% |
| Biomind Labs Inc. | 994.18 Thousand USD | 33.211% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.332% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 62.266% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 90.116% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 64.385% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2756.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 95.853% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 63.817% |
| GB Sciences, Inc. | 1.42 Million USD | 53.256% |
| Alpha Cognition Inc. | 9.7 Million USD | 93.159% |
| HST Global, Inc. | 140.9 Thousand USD | -371.233% |
| CSL Limited | 3.44 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 40.973% |
| Halberd Corporation | 74.84 Thousand USD | -787.202% |
| Enzolytics Inc. | 2.17 Million USD | 69.534% |
| Agentix Corp. | 1.37 Million USD | 51.595% |
| Resverlogix Corp. | 12.71 Million USD | 94.777% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 81.812% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.957% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 36.398% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 72.39% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 57.958% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 80.499% |
| AVAX Technologies, Inc. | 7.31 Million USD | 90.917% |
| Zenith Capital Corp. | 8.94 Million USD | 92.575% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.92% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -3711.492% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 72.957% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -287.152% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 65.433% |
| Kadimastem Ltd | 2.41 Million USD | 72.449% |
| Helix BioMedix, Inc. | 1.97 Million USD | 66.329% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 93.89% |
| BioStem Technologies, Inc. | 22.97 Million USD | 97.11% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -265.87% |
| LadRx Corporation | 3.81 Million USD | 82.58% |
| Cell Source, Inc. | 4.32 Million USD | 84.649% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 28.1% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 28.1% |
| NovAccess Global Inc. | 2.46 Million USD | 73.082% |
| Affymax, Inc. | 39.38 Million USD | 98.314% |
| Itoco Inc. | 919.14 Thousand USD | 27.759% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 84.334% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 40.661% |
| Mobile Lads Corp. | 554.54 Thousand USD | -19.738% |
| CytoDyn Inc. | 18.05 Million USD | 96.323% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -2538.166% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -201.711% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 53.233% |
| SYBLEU INC | 160.87 Thousand USD | -312.74% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 63.443% |
| International Stem Cell Corporation | 5.27 Million USD | 87.403% |
| Bioxytran, Inc. | 3.82 Million USD | 82.618% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1161.35% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -3164.022% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.169% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 58.962% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 9.762% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 78.656% |
| Neutra Corp. | 243.82 Thousand USD | -172.331% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 96.196% |
| PureTech Health plc | 144.59 Million USD | 99.541% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 96.759% |
| IXICO plc | 4.7 Million USD | 85.893% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 92.452% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.436% |
| CSL Limited | 3.89 Billion USD | 99.983% |
| Cellectis S.A. | 97.32 Million USD | 99.318% |